AT-07 / Attralus, Ossianix - LARVOL DELTA

Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023 (GlobeNewswire) - "Attralus...today announced new preclinical data for AT-04 and AT-07, the Company’s pan-amyloid removal (PAR) therapeutic candidates targeting neurodegenerative disorders. The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden....AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrils. AT-04 demonstrated in vivo target engagement and binding to Aβ plaques in 5xFAD mouse model. AT-04 and AT-07 demonstrated binding to Aβ plaques in brain tissue sections from patients with AD."

Preclinical • Alzheimer's Disease • CNS Disorders • Lewy Body Disease • Parkinson's Disease